1) If invoicing the Chinese, then the contract was
Post# of 36537
(Total Views: 323)
Posted On: 04/06/2020 1:04:32 PM
1) If invoicing the Chinese, then the contract was completed. At least some here indicated last week that it might not have been - but that should now be put to rest.
2) I thought the payments were milestone payments (except for the $1 million which was for expenses associated with typing the virus and antibodies). If so, then again, if they are invoicing the Chinese, there has been progress re: identifying/sequencing the virus to find the likely antibodies. Waiting on blood from Chinese/local sources so they can compare the natural antibodies with the simulated ones, to determine which are the best to proceed with to human tests, so again, progress with Epivax. If my terms are incorrect, please forgive dumb-a$$ railroad guy.
2a) I have wondered about this for a while now - if the CCP (Chinese Commie Party) is saying China has beaten the virus, is there an issue with the consortium continuing to publicly work with GNBT? Does the CCP really want to announce in 6 weeks (or 6 months, whatever) that suddenly, Shenzen has come up with a vaccine when previously, the CCP have been saying it's all controlled? Might explain why the consortium is not cooperating as quickly as possible - negative pressure from the top.
3) I don't see how any of this is stopping or slowing down the NGIO listing - the Form 10 was filed, now waiting for the SEC response so the share registration S-1 can be completed and filed. Then waiting for the SEC response prior to listing. If the CV19 work has not been completed by the time NGIO is ready to list, then the folks buying the IPO are gonna get a deal because if the CV19 work comes to fruition afterwards, the pps of NGIO is going up on that news.
4) Same as #3 for the funding S-1. Waiting on the SEC response - haven't heard anything yet asking for clarification or revision (or I think Joe would have mentioned it).
5) Still proceeding with other GNBT operations, but probably remaining slow to start because no funding (waiting for S-1, waiting for pps to increase so we don't give away the company?).
6) Nobody is watching GNBT closely, probably because of OTC. No real volume and again no anticipation of future achievements, even though they are laid out nicely in last paragraph. So I'm not getting any hope up that this does anything until 1) NGIO lists (or news on a date certain for listing) or 2) somebody big like a Merck comes in and says they are using GNBT's technology to develop X, Y or Z. Until one of those two actually happen, I believe we stay under $1, probably around $.50.
2) I thought the payments were milestone payments (except for the $1 million which was for expenses associated with typing the virus and antibodies). If so, then again, if they are invoicing the Chinese, there has been progress re: identifying/sequencing the virus to find the likely antibodies. Waiting on blood from Chinese/local sources so they can compare the natural antibodies with the simulated ones, to determine which are the best to proceed with to human tests, so again, progress with Epivax. If my terms are incorrect, please forgive dumb-a$$ railroad guy.
2a) I have wondered about this for a while now - if the CCP (Chinese Commie Party) is saying China has beaten the virus, is there an issue with the consortium continuing to publicly work with GNBT? Does the CCP really want to announce in 6 weeks (or 6 months, whatever) that suddenly, Shenzen has come up with a vaccine when previously, the CCP have been saying it's all controlled? Might explain why the consortium is not cooperating as quickly as possible - negative pressure from the top.
3) I don't see how any of this is stopping or slowing down the NGIO listing - the Form 10 was filed, now waiting for the SEC response so the share registration S-1 can be completed and filed. Then waiting for the SEC response prior to listing. If the CV19 work has not been completed by the time NGIO is ready to list, then the folks buying the IPO are gonna get a deal because if the CV19 work comes to fruition afterwards, the pps of NGIO is going up on that news.
4) Same as #3 for the funding S-1. Waiting on the SEC response - haven't heard anything yet asking for clarification or revision (or I think Joe would have mentioned it).
5) Still proceeding with other GNBT operations, but probably remaining slow to start because no funding (waiting for S-1, waiting for pps to increase so we don't give away the company?).
6) Nobody is watching GNBT closely, probably because of OTC. No real volume and again no anticipation of future achievements, even though they are laid out nicely in last paragraph. So I'm not getting any hope up that this does anything until 1) NGIO lists (or news on a date certain for listing) or 2) somebody big like a Merck comes in and says they are using GNBT's technology to develop X, Y or Z. Until one of those two actually happen, I believe we stay under $1, probably around $.50.
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼